Serum lipid metabolism in psoriasis and psoriatic arthritis - an update

被引:66
作者
Pietrzak, Aldona [1 ]
Chabros, Pawel [2 ]
Grywalska, Ewelina [3 ]
Kicinski, Pawel [4 ,5 ]
Franciszkiewicz-Pietrzak, Kinga [6 ]
Krasowska, Dorota [1 ]
Kandzierski, Grzegorz [7 ]
机构
[1] Med Univ Lublin, Dept Dermatol Venereol & Pediat Dermatol, 13 Radziwillowska St, PL-20080 Lublin, Poland
[2] Med Univ Lublin, Orthoped & Traumatol Dept, Lublin, Poland
[3] Med Univ Lublin, Dept Clin Immunol & Immunotherapy, Lublin, Poland
[4] Med Univ Lublin, Dept Expt Hematooncol, Lublin, Poland
[5] St Johns Canc Ctr, Dept Hematol, Lublin, Poland
[6] Med Univ Lublin, Dept Surg Oncol, Lublin, Poland
[7] Med Univ Lublin, Dept Paediat Orthopaed & Rehabil, Lublin, Poland
关键词
oxidative stress; cholesterol; apolipoprotein; lipid metabolism; CARDIOVASCULAR RISK-FACTORS; BIOMARKERS; DISEASE; ATHEROSCLEROSIS; EPIDEMIOLOGY; LIPOPROTEINS; ASSOCIATION; PREVALENCE; GUIDELINES; ANTIBODIES;
D O I
10.5114/aoms.2018.74021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Psoriasis and psoriatic arthritis (PSA) are chronic, inflammatory, systemic diseases characterized by metabolic abnormalities, including an increased cardiovascular risk and an oxidative imbalance. This study assessed blood parameters of lipid metabolism and markers of oxidative stress in patients with psoriasis and PSA. Material and methods: The study included 93 patients with psoriasis (31 patients with PSA and psoriasis, 62 patients with psoriasis vulgaris), and 60 healthy, age-matched controls. Serum concentrations of the glucose and the following lipid metabolism parameters were measured: triglycerides (TG), total cholesterol (TC), low-density lipoproteins (LDL), very low-density lipoproteins (VLDL), high-density lipoproteins (HDL), and apolipoproteins A and B (ApoA, ApoB). Oxidative status was determined as serum concentrations of ox-LDL/MDA Adduct. The Psoriasis Area and Severity Index (PASI) was used to determine disease severity. Results: Among the three studied groups, controls had the highest HDL concentration (p < 0.001), patients with PSA had the highest ApoB concentration (p < 0.05), ApoA : ApoB ratio (p < 0.05), ox-LDL/MDA adduct concentration (p < 0.001), and TC: HDL and LDL : HDL ratios (accordingly p < 0.05, p < 0.01). In patients with psoriasis or PSA, oxidative status correlated positively with TC and ApoB concentrations. Conclusions: In line with previous research, among patients with psoriasis and PSA, we found lipid metabolism abnormalities and an oxidative imbalance, which might be due to chronic inflammation in these conditions. Effective treatment of patients with psoriasis or PSA could reduce the risk of cardiovascular diseases.
引用
收藏
页码:369 / 375
页数:7
相关论文
共 38 条
[1]   Psoriasis and metabolic disease: epidemiology and pathophysiology [J].
Azfar, Rahat S. ;
Gelfand, Joel M. .
CURRENT OPINION IN RHEUMATOLOGY, 2008, 20 (04) :416-422
[2]   PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016 [J].
Banach, Maciej ;
Jankowski, Piotr ;
Jozwiak, Jacek ;
Cybulska, Barbara ;
Windak, Adam ;
Guzik, Tomasz ;
Mamcarf, Artur ;
Broncel, Marlena ;
Tomasik, Tomasz ;
Rysz, Jacek ;
Jankowska-Zdunczyk, Agnieszka ;
Hoffman, Piotr ;
Mastalerz-Migas, Agnieszka .
ARCHIVES OF MEDICAL SCIENCE, 2017, 13 (01) :1-45
[3]   Carotid intima-media thickness in patients with mild or moderate psoriasis [J].
Banska-Kisiel, Katarzyna ;
Haberka, Maciej ;
Bergler-Czop, Beata ;
Brzezinska-Wcislo, Ligia ;
Okopien, Boguslaw ;
Gasior, Zbigniew .
POSTEPY DERMATOLOGII I ALERGOLOGII, 2016, 33 (04) :286-289
[4]   Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus [J].
Batuca, J. R. ;
Ames, P. R. J. ;
Amaral, M. ;
Favas, C. ;
Isenberg, D. A. ;
Alves, J. Delgado .
RHEUMATOLOGY, 2009, 48 (01) :26-31
[5]   ANTI-APOLIPOPROTEIN A-I (APOA-I) ANTIBODIES HAVE DIFFERENT TARGET EPITOPES IN DIFFERENT CLINICAL CONDITIONS [J].
Batuca, Joana ;
Lamy, Marcia ;
Neves, Marisa ;
Batista, Frederico ;
Paiva-Lopes, Ma Joao ;
Valverde, Ana H. ;
Silva, Margarida ;
Mcvey, Colin E. ;
Archer, Margarida ;
Goncalves, Joao ;
Barbas, Ana ;
Bandeiras, Tiago M. ;
Carrondo, Ma Armenia ;
Alves, Jose Delgado .
ATHEROSCLEROSIS, 2017, 263 :E216-E217
[6]   Physical Activity, Antioxidant Status, and Protein Modification in Adolescent Athletes [J].
Carlsohn, Anja ;
Rohn, Sascha ;
Mayer, Frank ;
Schweigert, Florian J. .
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2010, 42 (06) :1131-1139
[7]   Psoriasis Therapy and Cardiovascular Risk Factors A 12-Week Follow-Up Study [J].
Coimbra, Susana ;
Oliveira, Hugo ;
Reis, Flavio ;
Belo, Luis ;
Rocha, Susana ;
Quintanilha, Alexandre ;
Figueiredo, Americo ;
Teixeira, Frederico ;
Castro, Elisabeth ;
Rocha-Pereira, Petronila ;
Santos-Silva, Alice .
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2010, 11 (06) :423-432
[8]   The plasma parameter log (TG/HDL-C) as an atherogenic index:: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FERHDL). [J].
Dobiásová, M ;
Frohlich, J .
CLINICAL BIOCHEMISTRY, 2001, 34 (07) :583-588
[9]   Plasma and scales levels of interleukin 18 in comparison with other possible clinical and laboratory biomarkers of psoriasis activity [J].
Flisiak, I ;
Klepacki, A ;
Chodynicka, B .
BIOMARKERS, 2006, 11 (02) :194-200
[10]   Association between small dense LDL and sub-clinical atherosclerosis in patients with psoriatic arthritis [J].
Gentile, Marco ;
Peluso, Rosario ;
Di Minno, Matteo Nicola Dario ;
Costa, Luisa ;
Caso, Francesco ;
de Simone, Biagio ;
Iannuzzo, Gabriella ;
Scarpa, Raffaele ;
Rubba, Paolo .
CLINICAL RHEUMATOLOGY, 2016, 35 (08) :2023-2029